Wound Care Biologics Market Report 2026

The wound care biologics market size has grown strongly in recent years. It will grow from $2.06 billion in 2025 to $2.24 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising prevalence of chronic wounds, increasing diabetic population, aging global population, limited effectiveness of conventional wound care, growing hospital and clinic infrastructure.

The wound care biologics market size is expected to see strong growth in the next few years. It will grow to $3.19 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to advancements in biologic skin substitutes, expansion of regenerative medicine, adoption of digital wound monitoring, increased r&d investment in wound care biologics, government initiatives supporting advanced therapies. Major trends in the forecast period include advanced wound healing technologies, increased adoption of biologic skin substitutes, antimicrobial resistance management, personalized wound care solutions, integration of regenerative medicine approaches.

The rising prevalence of diabetes is expected to drive the growth of the wound care biologics market in the coming years. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels, which over time can cause severe damage to the heart, blood vessels, eyes, kidneys, and nerves. Biological wound care products help prevent fluid, protein, and electrolyte loss, reduce contamination risk, and promote autolytic debridement while supporting the formation of granular tissue. For instance, in June 2024, the UK’s National Health Service (NHS) reported that among individuals under 40, diabetes cases rose from 173,166 in 2022 to 216,440 in 2023, highlighting a concerning increase in younger populations. Therefore, the high prevalence of diabetes is fueling the demand for effective wound care biologics.

Leading companies in the wound care biologics market are developing advanced materials, such as bioengineered electrospun synthetic polymer matrices, to improve healing and tissue regeneration. These matrices act as scaffolds that facilitate cellular migration, promote tissue repair, and accelerate wound closure. For example, in October 2024, Royal Biologics, a US-based orthobiologics company, launched the Peak Powder Collagen Matrix, which creates a gel-like barrier supporting tissue regeneration, and ElectroFiber 3D, a bioengineered matrix that enhances cellular migration and reduces healing time.

In July 2023, Coloplast, a US-based healthcare company, acquired Kerecis for $1.3 billion. The acquisition allows Coloplast to strengthen its position in the advanced wound care market by integrating Kerecis’s innovative fish skin technology for chronic wounds and surgical applications. Kerecis, based in Iceland, continues to operate as a standalone business unit, while the deal enables Coloplast to expand its revenue, improve gross margins, and increase long-term growth guidance.

Major companies operating in the wound care biologics market are Integra Lifesciences Corporation, Organogenesis Inc., Smith and Nephew plc, Wright Medical Group NV, MiMedx Group Inc., Kerecis AG, Amnio Technology LLC, Anika Therapeutics Inc., ACell Inc., Derma Sciences Inc., Soluble Systems Pvt. Ltd., Medline Industries LP, Solsys Medical LLC, Zimmer Biomet Holdings Inc., MLM Biologics Inc., Tissue Genesis LLC, Stryker Corporation, Marine Polymer Technologies Inc., Bioventus Inc., Mölnlycke Health Care AB, Lynch Biologics LLC, Skye Biologics Holdings LLC, Osiris Therapeutics Inc., Vericel Corporation, TissueTech Inc., PolarityTE Inc., Avita Medical Limited, Celularity Inc., Human Regenerative Technologies LLC, PolyRemedy Inc.

North America was the largest region in the wound care biologics market in 2025.Asia-pacific is expected to be the fastest-growing region in the global wound care biologics market report during the forecast period. The regions covered in the wound care biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the wound care biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the wound care biologics market by affecting the cost and supply of imported biologic materials and advanced wound care devices. The resulting increase in production costs and delays impacts hospitals, burn centers, and wound clinics, particularly in regions like north america, europe, and asia-pacific that rely heavily on imports. The acellular, cellular, and composite skin substitutes segments are most affected due to reliance on specialized materials. However, tariffs also incentivize local manufacturing and innovation, potentially reducing dependence on imports and strengthening domestic supply chains.

The wound care biologics market research report is one of a series of new reports that provides wound care biologics market statistics, including wound care biologics industry global market size, regional shares, competitors with a wound care biologics market share, detailed wound care biologics market segments, market trends and opportunities, and any further data you may need to thrive in the wound care biologics industry. This wound care biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Wound care biologics are bioengineered products used to treat non-healing wounds of the lower extremities. They are increasingly recognized in wound care for their ability to manage exudates and protect against bacterial infections.

The main products in wound care biologics include biologic skin substitutes and topical agents. Biologic skin substitutes, also known as tissue-engineered products or artificial skin, support wound healing by promoting the formation of new tissue and have proven highly beneficial in medical practice. Wound care biologics are used to treat ulcers, surgical wounds, traumatic wounds, and burns, with end users including hospitals, ambulatory surgical centers (ASCs), burn centers, and specialized wound clinics.

The wound care biologics market consists of revenues earned by entities by providing wound care services such as surgical and traumatic wounds, burns chronic wounds and acute Wounds. The market value includes the value of related goods sold by the service provider or included within the service offering. The wound care biologics market also includes sales of surgical equipment's, medical tape, sponges, cotton pads which are used in providing wound care biologics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.